



ASX Announcement | 4 September 2025
AdAlta Limited (ASX:1AD)

Upcoming AdAlta investor presentations including bi-lingual RCA Webinar

AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), developer of next generation cell and protein therapeutic products is presenting at two upcoming events, including a bi-lingual virtual investor presentation at Resource Connect Asia’s next Technology Webinar.

On 12 September 2025, AdAlta’s CEO and Managing Director, Dr Tim Oldham will participate in a bi-lingual Resource Connect Asia Technology Webinar. Dr Oldham will discuss the pillars powering AdAlta’s “East to West” cellular immunotherapy strategy:

- The China innovation boom that is disrupting the global biotech ecosystem;
- The extraordinary power of reprogrammed human immune cells as living drugs to fight cancer;
- The steps AdAlta is taking to bring these incredible innovations to global patients using Australian expertise and the opportunities this creates for AdAlta shareholders.

The presentation and questions will be in English with Mandarin Chinese subtitles. Details are:

RCA/TechKnow Technology Webinar Series
10:00am – 12:00 noon Perth/Singapore/Beijing time/12:00 noon – 2:00pm AEST
Friday, 12 September 2025
Free registration here: https://us06web.zoom.us/webinar/register/WN_f6dtPXG-TtWfqv3ifMx-8g

To view additional content after the event, visit AdAlta’s InvestorHub here:
<https://investorhub.adalta.com.au/link/yVwBGe>

Additionally, on 10 September 2025, Dr Oldham will present at Asia Bio Partnering Forum in Singapore, the premier Asia-Pacific biopharma conference for global cross-border partnerships that is accelerating Asia-Pacific’s life science innovation through strategic global partnerships and emerging biotech opportunities. Details are:

11:05am Singapore time/1:05pm AEST
Wednesday, 10 September 2025
Marina Bay Sands, Singapore
Registration here: <https://informaconnect.com/asia-bio-partnering-forum/registration-options/>

This ASX announcement has been authorised for release by the CEO of AdAlta Limited (ASX:1AD).

For further information, please contact:

AdAlta Limited (ASX:1AD)
Tim Oldham
CEO & Managing Director
P: +61 3 9479 5159
E: t.oldham@adalta.com.au

About AdAlta

AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers.

Through its 'East to West' strategy, the Company is integrating Asia's prowess in T cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem to create a pathway connecting 'Eastern' innovation in cellular immunotherapies with 'Western' regulated markets and patients.

AdAlta in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies with potential to position each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialization.

AdAlta implements a disciplined approach to asset selection focused on highly differentiated T cell therapy products supported by clinical data in solid cancers. The company adopts a capital efficient business model delivering a rapid return on investment in each project that is replicable and provides opportunities to scale across multiple products.

Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies. AdAlta aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow at a compound annual growth rate of 34% to reach US\$20.3 billion by 2028.

AdAlta's first in class fusion protein, AD-214, takes a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis. Following demonstration of efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is available for partnering.

To learn more, please visit: www.adalta.com.au

For more information



Join our [InvestorHub](#)



Follow us on [LinkedIn](#)



Follow us on [X \(formerly Twitter\)](#)